Chronic myeloproliferative disorders

Charlotte M. Niemeyer, Franco Locatelli

Research output: Chapter in Book/Report/Conference proceedingChapter

17 Citations (Scopus)

Abstract

Introduction In 1951, Dameshek first speculated on the observation that different chronic proliferative disorders share similar clinical and hematologic features and that patients with one of these diseases often develop, during the course of their illness, symptoms more typical of another disease, usually more severe than the original one. He coined the term “myeloproliferative disorders” (MPD) for these, now widely recognized, clonal proliferations of an abnormal hematopoietic stem cell. This group of related diseases, characterized by a variable propensity to evolve into acute leukemia, included chronic myeloid leukemia (CML), polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia (currently referred to as chronic idiopathic myelofibrosis). More than 50 years later, this classification, which is applicable to both adults and children, still maintains its clinical and biologic value. Apart from these acquired hematopoietic neoplasms, rare congenital genetic abnormalities can give rise to myeloproliferative disorders (Table 22.1). Myeloid neoplasms that present with aberrant proliferative and dysplastic features have raised considerable controversy with respect to their classification. The recent classification system of the World Health Organization (WHO) groups these diseases with their variable effective or dysplastic hematopoiesis into a separate category of myelodysplastic/myeloproliferative disorders, including juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), atypical CML and a group of otherwise unclassifiable diseases. While JMML represents about 2% to 3% of leukemias in children, CMML and atypical CML are extremely rare in young people. CMML is occasionally diagnosed in an adolescent with persistent monocytosis, low blast count, and the absence of genetic features indicating JMML or CML.

Original languageEnglish
Title of host publicationChildhood Leukemias, Second Edition
PublisherCambridge University Press
Pages571-598
Number of pages28
ISBN (Print)9780511471001, 0521825199, 9780521825191
DOIs
Publication statusPublished - Jan 1 2006

Fingerprint

Myeloproliferative Disorders
Juvenile Myelomonocytic Leukemia
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia
Essential Thrombocythemia
Polycythemia Vera
Hematopoiesis
Hematologic Neoplasms
Hematopoietic Stem Cells
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Niemeyer, C. M., & Locatelli, F. (2006). Chronic myeloproliferative disorders. In Childhood Leukemias, Second Edition (pp. 571-598). Cambridge University Press. https://doi.org/10.1017/CBO9780511471001.023

Chronic myeloproliferative disorders. / Niemeyer, Charlotte M.; Locatelli, Franco.

Childhood Leukemias, Second Edition. Cambridge University Press, 2006. p. 571-598.

Research output: Chapter in Book/Report/Conference proceedingChapter

Niemeyer, CM & Locatelli, F 2006, Chronic myeloproliferative disorders. in Childhood Leukemias, Second Edition. Cambridge University Press, pp. 571-598. https://doi.org/10.1017/CBO9780511471001.023
Niemeyer CM, Locatelli F. Chronic myeloproliferative disorders. In Childhood Leukemias, Second Edition. Cambridge University Press. 2006. p. 571-598 https://doi.org/10.1017/CBO9780511471001.023
Niemeyer, Charlotte M. ; Locatelli, Franco. / Chronic myeloproliferative disorders. Childhood Leukemias, Second Edition. Cambridge University Press, 2006. pp. 571-598
@inbook{0199af056e4b4a61961fab2922d26f54,
title = "Chronic myeloproliferative disorders",
abstract = "Introduction In 1951, Dameshek first speculated on the observation that different chronic proliferative disorders share similar clinical and hematologic features and that patients with one of these diseases often develop, during the course of their illness, symptoms more typical of another disease, usually more severe than the original one. He coined the term “myeloproliferative disorders” (MPD) for these, now widely recognized, clonal proliferations of an abnormal hematopoietic stem cell. This group of related diseases, characterized by a variable propensity to evolve into acute leukemia, included chronic myeloid leukemia (CML), polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia (currently referred to as chronic idiopathic myelofibrosis). More than 50 years later, this classification, which is applicable to both adults and children, still maintains its clinical and biologic value. Apart from these acquired hematopoietic neoplasms, rare congenital genetic abnormalities can give rise to myeloproliferative disorders (Table 22.1). Myeloid neoplasms that present with aberrant proliferative and dysplastic features have raised considerable controversy with respect to their classification. The recent classification system of the World Health Organization (WHO) groups these diseases with their variable effective or dysplastic hematopoiesis into a separate category of myelodysplastic/myeloproliferative disorders, including juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), atypical CML and a group of otherwise unclassifiable diseases. While JMML represents about 2{\%} to 3{\%} of leukemias in children, CMML and atypical CML are extremely rare in young people. CMML is occasionally diagnosed in an adolescent with persistent monocytosis, low blast count, and the absence of genetic features indicating JMML or CML.",
author = "Niemeyer, {Charlotte M.} and Franco Locatelli",
year = "2006",
month = "1",
day = "1",
doi = "10.1017/CBO9780511471001.023",
language = "English",
isbn = "9780511471001",
pages = "571--598",
booktitle = "Childhood Leukemias, Second Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Chronic myeloproliferative disorders

AU - Niemeyer, Charlotte M.

AU - Locatelli, Franco

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Introduction In 1951, Dameshek first speculated on the observation that different chronic proliferative disorders share similar clinical and hematologic features and that patients with one of these diseases often develop, during the course of their illness, symptoms more typical of another disease, usually more severe than the original one. He coined the term “myeloproliferative disorders” (MPD) for these, now widely recognized, clonal proliferations of an abnormal hematopoietic stem cell. This group of related diseases, characterized by a variable propensity to evolve into acute leukemia, included chronic myeloid leukemia (CML), polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia (currently referred to as chronic idiopathic myelofibrosis). More than 50 years later, this classification, which is applicable to both adults and children, still maintains its clinical and biologic value. Apart from these acquired hematopoietic neoplasms, rare congenital genetic abnormalities can give rise to myeloproliferative disorders (Table 22.1). Myeloid neoplasms that present with aberrant proliferative and dysplastic features have raised considerable controversy with respect to their classification. The recent classification system of the World Health Organization (WHO) groups these diseases with their variable effective or dysplastic hematopoiesis into a separate category of myelodysplastic/myeloproliferative disorders, including juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), atypical CML and a group of otherwise unclassifiable diseases. While JMML represents about 2% to 3% of leukemias in children, CMML and atypical CML are extremely rare in young people. CMML is occasionally diagnosed in an adolescent with persistent monocytosis, low blast count, and the absence of genetic features indicating JMML or CML.

AB - Introduction In 1951, Dameshek first speculated on the observation that different chronic proliferative disorders share similar clinical and hematologic features and that patients with one of these diseases often develop, during the course of their illness, symptoms more typical of another disease, usually more severe than the original one. He coined the term “myeloproliferative disorders” (MPD) for these, now widely recognized, clonal proliferations of an abnormal hematopoietic stem cell. This group of related diseases, characterized by a variable propensity to evolve into acute leukemia, included chronic myeloid leukemia (CML), polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia (currently referred to as chronic idiopathic myelofibrosis). More than 50 years later, this classification, which is applicable to both adults and children, still maintains its clinical and biologic value. Apart from these acquired hematopoietic neoplasms, rare congenital genetic abnormalities can give rise to myeloproliferative disorders (Table 22.1). Myeloid neoplasms that present with aberrant proliferative and dysplastic features have raised considerable controversy with respect to their classification. The recent classification system of the World Health Organization (WHO) groups these diseases with their variable effective or dysplastic hematopoiesis into a separate category of myelodysplastic/myeloproliferative disorders, including juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), atypical CML and a group of otherwise unclassifiable diseases. While JMML represents about 2% to 3% of leukemias in children, CMML and atypical CML are extremely rare in young people. CMML is occasionally diagnosed in an adolescent with persistent monocytosis, low blast count, and the absence of genetic features indicating JMML or CML.

UR - http://www.scopus.com/inward/record.url?scp=34548121797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548121797&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511471001.023

DO - 10.1017/CBO9780511471001.023

M3 - Chapter

SN - 9780511471001

SN - 0521825199

SN - 9780521825191

SP - 571

EP - 598

BT - Childhood Leukemias, Second Edition

PB - Cambridge University Press

ER -